Key facts
- It has raised $54.8M; the latest was Later Stage VC ($34.0M) in Oct 2024.
- Notable investors include High-Tech Gründerfonds, IBB Ventures, Mayo Clinic, Boehringer Ingelheim Venture Fund, Wellington Partners — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Aignostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aignostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aignostics
Developer of an artificial intelligence-based image analysis system designed to develop best-in-class insights for the next generation of precision medicine. The company's platform works on decoding pathology for precision medicine to discover tissue-based biomarkers to drastically improve the diagnosis and treatment of cancer and other complex diseases by rendering diagnostic results explainable in the form of precise heatmaps and image overlays for diagnosing degenerative, infectious, and inflammatory diseases, enabling pathologists to quickly verify the results of the artificial intelligence to support precision medicine and drug development processes.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2018
- Employees
- 120
- Website
- aignostics.com/
- Ownership
- Privately Held (backing)
Aignostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aignostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aignostics in its N-PORT filings yet. We sweep new filings monthly.